FORM PTO-1449

(Use several sheets if necessary)

LIST OF DISCLOSURES CITED BY APPLICANTER

U.S. Dept. of Commerce Patent and Trademark Office Atty Docket No. P1752R1

Serial No. 09/613,038

**Applicant** 

Grillo-Lopez et al.

RECEIVED

Filing Date 10 Jul 2000 Group 1636 JAN 1 0 2001

|                      |        |  |                     | U.S. PATENT DOCUMENTS  |                  |              |                                   |
|----------------------|--------|--|---------------------|--|------------------|--------------|-----------------------------------|
| Examiner<br>Initials |        | Document Number  | Date                | Name   | Class            | Subclass     | CH CENTER 1605,799<br>Filing Date |
| an                   | 80     | 5,795,967  | 18.08.98            | Aggarwal et al.  | 530              | 388.23       |                                   |
|                      |        |  |                     | FOREIGN PATENT DOCUMENTS   |                  |              |                                   |
| Examiner<br>Initials |        | Document Number  | Date                | Country  | Class            | Subclass     | Translation<br>Yes No             |
| EN                   | 81     | WO 00/67796 •  | 16.11.00            | PCT  |                  |              |                                   |
| (SW)                 | 82     | WO 00/74718 6  | 14.12.00            | PCT  | <u> </u>         |              | حــــــا                          |
| and                  | 83     | wo 00/76542  | 21.12.00            | PCT  |                  |              |                                   |
| i .                  | 84     | WO 94/27638 &  | 08.12.94            | PCT  |                  | <del> </del> |                                   |
| @N                   | 85     | WO 99/54440 • .  | 28.10.99            | PCT  |                  |              |                                   |
|                      |        |  |                     | OSURES (Including Author, Title, Date, Perti   | •                | •            |                                   |
| QN                   | 86     | Leget et al., "Use of rituximab, the new FDA-approved antibody" <u>Current Opinion in Oncology</u> 10(6):548-551 (Nov 1998)  |                     |  |                  |              |                                   |
| an                   | 87     | Protheroe et al., "Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma" Rheumatology (Oxford) 38(11):1150-1152 (Nov 1999) :                                       |                     |  |                  |              |                                   |
| QN                   | 88     | Qu et al., "Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates" <u>Journal of Immunological Methods</u> 213(2):131-144 (Apr 15, 1998)             |                     |  |                  |              |                                   |
| an                   | 89     | Rowan et al., "Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells" Immunology 95(3):427-436 (Nov 1998) |                     |  |                  |              |                                   |
| QN                   | 90     | Stein et al., "Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2" Cancer Immunology, Immunotherapy 37(5):293-298 (Oct 1993)   |                     |  |                  |              |                                   |
| an                   | 91     | Theocharis et al., "Characterization of in vivo mutated T cell clones from patients with systemic luperythematosus" Clinical Immunology & Immunopathology 74(2):135-142 (Feb 1995).                                  |                     |  |                  |              |                                   |
| ļ                    |        |  |                     | _  |                  |              | _                                 |
|                      | -      |  |                     |  | -                | <del></del>  |                                   |
|                      |        |  |                     |  | -                |              |                                   |
|                      |        |  |                     |  |                  |              |                                   |
|                      |        |  |                     |  |                  | <u></u>      |                                   |
|                      | -      |  | <del></del> _       |  |                  | •            |                                   |
|                      |        |  | -                   |  |                  |              |                                   |
| Examine              | r      |  |                     |  | onsidered        |              |                                   |
|                      |        | Quan No  | men                 |  | b 28/            | <u>O</u>     |                                   |
| *Examin              | er: In | itial if reference consider  | ered, Whether or no | ot citation is in conformance with MPEP 609;<br>by of this form with next communication to ap  | draw line throug | h citation   |                                   |
| ,,,,,,               |        |  |                     | The second state of the second | L                |              |                                   |